Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

Kancera närmar sig utlicensiering – och byter namn

Forskningsbolaget Kancera har ingått en avsiktsförklaring med amerikanska Recardio om en utlicensiering av företagets två läkemedelskandidater Kand567 och Kand145 för intervention vid akut hjärtinfarkt.

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.

Hansa tar in 372 miljoner inför USA-lansering: "Starkt intresse"

Lundbaserade Hansa Biopharma har tagit in 372,2 miljoner kronor i en riktad nyemission där flera amerikanska specialistinvesterare deltar.

Failed to read the fine print – lost his life’s work

A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story of a Swedish entrepreneur who was going to raise US venture capital to strengthen his company

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic have achieved just that, and they are thus making a significant contribution to the history of Swedish medicine. He is now being awarded the Research!Sweden Award 2023.

Study names with an attitude – more important than you might think

Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.

Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president

In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According to the reporter Theo Baker, who first reported the story, Tessier-Lavigne “rewarded

Anna Törner: The minute between life and death

“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try to understand why I haven’t told anyone, I find the answer: a feeling of shame. There is no forgiveness for something like this, even though it is very human to be distracted for a moment,” Anna Törner writes in a column.

He got inside the head of Sweden’s vaccine hunter

The hunt for the COVID-19 vaccine is the theme of the new book Vaccinjägaren (The Vaccine Hunter). It tells the story of Richard Bergström’s mission as Sweden’s national vaccine coordinator and the scheming that went on behind the scenes in Europe

Missnöjd med din julklappsslips? Här är våra läsetips

Anna Törner: Kalashnikovs in a new guise

Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American pharmaceutical authority, the Food and Drug Administration (FDA), refused to approve thalidomide (Neurosedyn), writes Anna Törner in a column.

Björn Arvidsson: “We need robust and recognized ecosystems for continued competitiveness”

“We have idea carriers and excellent innovation opportunities, and now we must invest in creating ecosystems that provide them with even better growth opportunities,” Björn Arvidsson writes in a column.

Column: Why there cannot be a complete cure for cancer – but there is certainly another way!

"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.

Björn Arvidsson: Let's build on the positive momentum

Progress needs narratives and heroes, and more than ever, going into the new year feels like an opportunity for a fresh start.

Carolin Wiken: Guldålder av uppmärksamhet demokratiserar vetenskap

Relevansen för begriplig vetenskapskommunikation har aldrig varit större, skriver Carolin Wiken, partner på Paues Åberg Communications, i en krönika.

”Newsify your equity story!”

En uppmaning till noterade life science-bolag att uppgradera sin kommunikation från ”plikt” till värdebyggare

Femte förslaget till regeringen från SwedenBio

Skärp målsättningen för deltagandet i EU:s ramprogram. Det är SwedenBios femte förslag inför den kommande forskningspropositionen.

Bayer lägger bud på Algeta

Tysk-norsk storaffär ger bränsle i biotech-branschen. I Sverige stiger aktiekursen i bolag som Active Biotech.

Happy exhibitors!

There were fewer vistors this year but most exhibitors are content.

Will the industry follow the economic revival?

Welcome to the eleventh Biotech Forum + Scanlab Fair!

A crash course in IP strategy

"Publish, publish, publish!" Sound familiar? So to meet the researcher's wishes, do you scribble a patent application with lipstick on a napkin and send it in? At the seminar Patent Strategies in the Biotech Company, you will have the chance to find out why this might not be the best idea.